Here, we analyzed rare IAR CD4+ T cells in PBMCs collected at baseline from alefacept- and placebo-treated new-onset T1D patients enrolled in the T1DAL clinical trial with the goal of identifying characteristics of autoreactive CD4+ T cells that predicted response to therapy. This evidence concerns the gene CD4 and type 1 diabetes mellitus.